Circulating Tumor Cells Market Size Worth $30.78 Billion By 2029 | CAGR: 14.9%

Circulating Tumor Cells Market Size Worth $30.78 Billion By 2029 | CAGR: 14.9%

The global circulating tumor cells market size is expected to reach USD 30.78 Billion by 2029 according to a new study by Polaris Market Research. The report “Circulating Tumor Cells Market Share, Size, Trends, Industry Analysis Report, By Technology (CTC Detection & Enrichment Methods, CTC Direct Detection Methods, CTC Analysis); By Application (Clinical/Liquid Biopsy, Research); By Product; By Specimen; By Region; Segment Forecast, 2022 - 2029” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Cancer cells that have split away from the main lump and appear in the circulatory system as single units or clusters are known as CTCs. Increasing prevalence of cancer disease, increasing R&D activities of therapies, and increased demand for personalized medicine are driving the circulating tumor cells market growth.


In 2021, the North American region accounted for the largest share in the global industry. The U.S is among the major countries across the world, which spends heavenly in the healthcare sector. Furthermore, with the rising cases of different types of cancer disease, the growing need for preventative medicine and companion diagnostics are driving the industry in the region.


Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below:



The devices segment holds the largest share in 2021. This is due to the large range of products available in this area, as well as upcoming advancements in microfluidics technology.



Key industry players are AVIVA Biosciences BIOCEPT, Inc., BioFluidica, BioCEP Ltd, Biolidics Limited, Canopus Bioscience Ltd., Creativ MicroTech, Inc., Bio-Techne Corporation, Epic Sciences, Greiner Bio-One International GmbH, Fluxion Biosciences, Inc., Ikonisys Inc, IVDiagnostics, LineaRx, Inc. (Vitatex, Inc.), Menarini Silicon Biosystems, Miltenyi Biotec, Precision for Medicine, LungLife AI, Inc., QIAGEN, ScreenCell, STEMCELL Technologies, Inc., Sysmex Corporation.



Polaris Market Research has segmented the circulating tumor cells market report on the basis of technology, application, product, specimen, and region:


Circulating Tumor Cells, Technology Outlook (Revenue - USD Million, 2017 - 2029)

  • Circulating Tumor Cells Detection & Enrichment Methods
    • Immunocapture
    • Size-based Separation
    • Density-based Separation
    • Combined Methods
  • Circulating Tumor Cells Direct Detection Methods
    • SERS
    • Microscopy
    • Others
  • Circulating Tumor Cells Analysis

Circulating Tumor Cells, Application Outlook (Revenue - USD Million, 2017 - 2029)

  • Clinical/Liquid Biopsy
  • Research

Circulating Tumor Cells, Product Outlook (Revenue - USD Million, 2017 - 2029)

  • Kits & Reagents
  • Blood Collection Tubes
  • Devices or Systems

Circulating Tumor Cells, Specimen Outlook (Revenue - USD Million, 2017 - 2029)

  • Blood
  • Bone Marrow
  • Other Body Fluids

Circulating Tumor Cells, Regional Outlook (Revenue - USD Million, 2017 - 2029)

  • North America
    • U.S.
    • Canada
  • Europe
    • France
    • Germany
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Mexico
    • Brazil
    • Argentina
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • Rest of Middle East & Africa